Introduction
malignant haematological disorders, AML, death, haematological malignancies
REMISSION, INVASIVE ASPERGILLOSIS, AML
The incidence of invasive aspergillosis (IA) in patients with haematological malignancies ranges from 4 (with prophylaxis) to 11% (without prophylaxis) during remission induction chemotherapy and is approximately 8% after allogeneic stem cell transplantation (SCT) [AML is mostly seen in older patients with a median age of around 70 years [In the past years overall survival has improved for younger AML patients, mostly due to improved supportive care and improvements of allogeneic-SCT [Study objectives were to estimate the cumulative incidence of death due to different CODs and to investigate the effect of IA on each separate COD in a cohort of older patients with AML (≥ 61 years) or high-risk MDS included in the Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) 43 randomized controlled trial. The HOVON focuses on improving treatment methods for adult patients with malignant haematological disorders by implementing randomized controlled trials.